| HOME | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|---|
| ||||||||||||||||||||||||||||||||
a Department of Exercise Science, The University of Georgia, Athens
Gary Alton Dudley, Department of Exercise Science, The University of Georgia, 115M Ramsey Center, 300 River Road, Athens, GA 30602-3654 E-mail: gdudley{at}coe.uga.edu.
Decision Editor: John E. Morley, MB, BCh
| Abstract |
|---|
|
|
|---|
Methods. In this double-blind crossover study, 10 men and 5 women (aged 60 ± 2 years, mean ± SE) consumed naproxen sodium or placebo for 10 days after performing 64 unilateral eccentric (ECC) knee extensions using 75% of the ECC 1-repetition maximum. Strength was measured before, 3 days after, and 10 days after each bout. Injury and soreness were assessed using magnetic resonance images of m. quadriceps femoris (QF) and a visual analog scale.
Results. Three days after exercise, concentric strength loss was greater for placebo (-32 ± 9%) than NSAID (-6 ± 8%; p = .0064). Likewise, isometric strength declined less for NSAID than placebo (-12 ± 7% vs -24 ± 4%; p = .0213), and thigh soreness while rising from a chair was greater for placebo (p
.0393) than NSAID (43 ± 7 mm vs 26 ± 7 mm). QF cross-sectional area (cm2) showing elevated T2 was 27% and 35% greater (p
.0096) for placebo on Days 3 and 10, respectively.
Conclusions. Naproxen sodium attenuated muscle injury, strength loss, and soreness following ECC exercise in older individuals and may be beneficial during the early stages of increased physical activity.
DELAYED-ONSET soreness arises from eccentric (ECC) muscle actions (1)(2). Walking down stairs, sitting down in a chair, and gardening, for example, involve ECC actions (3). Many older individuals experience disuse and weakness, due to their sedentary lifestyle, or hospitalization that may predispose them to muscle dysfunction, injury, and soreness upon remobilization or increased physical activity (4)(5). Older individuals are also increasingly encouraged to become physically active or to become mobile as soon as possible following inactivity. However, older adults recover strength slower (6) and show equivalent or greater fiber damage (7)(8)(9) than young adults following ECC exercise. Older individuals also often consume over-the-counter (OCT) nonsteroidal anti-inflammatory drugs (NSAIDs) for soreness. It is not known, however, if NSAIDs protect against exercise-induced muscle injury and dysfunction in this population. We recently found that an OCT NSAID attenuated exercise-induced inflammation, strength loss, and soreness in young adult males (10). This study examined the efficacy of naproxen sodium for exercise-induced muscle strength loss, injury, and soreness in older adults.
| Methods |
|---|
|
|
|---|
Participants
Fifteen healthy, but not resistance-trained, men (n = 10) and women (n = 5) participated in this study (aged 60 ± 2 years, height 176 ± 2 cm, and weight 80 ± 4 kg; mean ± SE). Procedures, risks, and benefits of the study were explained, and informed written consent was obtained from each subject after approval from the Institutional Review Board of The University of Georgia. No subjects reported taking NSAIDs during the month prior to the study. During the study, participants were told to take only the prescribed NSAID or placebo.
Testing and Exercise Procedures
Unilateral QF concentric 1-RM tests and ECC exercise were performed on a knee extension machine (Badger-Magnum; Milwaukee, WI) after familiarization (5)(10)(13) that consisted of two 1-RM's per week for 4 weeks. The 1-RM increased about 20% over the four sessions, mainly from Week 1 to Week 2 (Table 1 ). The load for the ECC bout (75% of the ECC 1-RM) was estimated from the CON 1-RM for two reasons: (i) the ECC 1-RM can be estimated from the CON 1-RM and it is approximately 40% greater (15), and (ii) we did not expose subjects to ECC exercise before their ECC bout to avoid a "protective effect" (12)(13). The goal of the ECC bout was to perform 8 sets of 7 to 10 ECC repetitions with 90 seconds rest between sets (5)(10)(13)(14). The load was reduced to allow completion of 7 to 10 repetitions.
|
Pharmacology
Participants consumed one capsule of naproxen sodium (220 mg) or placebo (sucrose) three times a day (every 8 hours) for 10 days, beginning immediately after the ECC bout. The total daily dosage (660 mg) is the maximum recommended OCT. After a 3-week washout, subjects performed the second ECC bout (using the contralateral QF) before undergoing the crossed-over treatment for 10 days. Capsules were prepackaged such that neither the investigator nor the participants knew condition of the capsules. All capsule containers returned to the investigator after the study were empty, suggesting 100% compliance.
Magnetic Resonance Imaging
Muscle injury was assessed with MR imaging (5)(10)(14). Transaxial images (TR/TE 2000/30 60, 256 by 256 matrix, 40 cm FOV, 1 NEX) 1.0-cm thick with a 0.5-cm gap between slices were obtained from the knee joint to the head of the femur. MR images were transferred to a Macintosh (Cupertino, CA) computer for determination of muscle cross-sectional area (CSA) and T2 using NIH Image (National Institutes of Health, Bethesda, MD; 5,10,14). For each participant, data were averaged over the 12 contiguous images immediately inferior to the m. gluteus maximus. The reliability (squared intraclass correlation coefficient [R2]) of a CSA measure on different days was .98.
Soreness Ratings
Subjects rated soreness in each QF on a visual analog scale when seated with the hips and knees at approximately 90° and while standing up without upper body assistance (16). The 100-mm visual analog scale was anchored with "no pain" and "extremely painful."
Statistical Analyses
Variables were analyzed with a two-way repeated measures (treatment x time) ANOVA. If the sphericity assumption was not met, the Huyne-Feldt adjustment was made to the level of probability so that the F ratio was not positively biased (17). Specific differences were analyzed by the least squares means test. The level of statistical significance was set at p < .05. All data are presented as mean ± SE.
| Results |
|---|
|
|
|---|
|
.3816). However, upon standing, less soreness was reported with the drug than with placebo 3 days after the ECC bout (p
.0393) (Table 2 ).
Muscle Injury
The relative CSA with an elevated T2 was 27% and 35% greater (p
.0096) for placebo than NSAID on Days 3 and 10 of recovery, respectively (Table 2 ). Neither CSA of the QF nor whole muscle T2 showed a main effect for treatment or treatment-by-time interaction (p
.7951) (Table 2 ). Following novel ECC exercise, the time effect for CSA (cm2) of the QF (p = .0001) was reflected in the 11 ± 2% increase on Day 3 that had not recovered by Day 10 (Table 2 ). Whole-muscle T2 increased (p = .0001) from 32.01 ± 0.30 milliseconds to 36.47 ± 0.94 milliseconds, pre-exercise to Day 3, and remained elevated on Day 10 (p = 0.0007) (Table 2 ).
| Discussion |
|---|
|
|
|---|
The 1-RM and isometric strength were reduced 32% and 24%, respectively, 3 days after ECC exercise. This compares well with responses in younger groups (5)(10)(13)(14). Also, the QF showed increases in CSA and T2 on Day 3 of recovery; these increases were comparable to previous research in young adults (10). The placebo group experienced injury in approximately 40% of the muscle as reflected by T2 contrast shifts. This agrees with other studies that indicate that ECC exercise may damage
50% of the fibers in the involved muscle (1)(7) but is greater than the values reported more recently (8)(9).
The primary finding of this study was that naproxen sodium attenuates the loss of muscle function following ECC exercise. This was mostly likely mediated by the anti-inflammatory actions of the drug on the exercised muscle tissue. Naproxen sodium is both an analgesic and an anti-inflammatory that competitively inhibits the cyclooxygenase enzyme, thereby reducing prostaglandin E2 (PGE2) synthesis. By reducing the perfusion and/or muscle protein degradation triggered by PGE2, naproxen may also reduce muscle edema following injurious exercise (30). Naproxen may also relieve soreness by desensitizing type IV afferent nerve endings, which transmit dull, aching pain to higher centers via PGE2 (30). We have suggested that NSAIDs reduce exercise-induced muscle injury and dysfunction by attenuating the inflammatory response (10). As in that report, drug treatment was initiated in this study following exercise. Hence, naproxen could only have affected events subsequent to the ECC bout, rather than those that caused the initial injury.
The present observations agree with our strength and muscle injury data from younger participants who exercised with 85% of the ECC 1-RM (10). The younger volunteers also reported less muscle soreness during naproxen sodium treatment (10). However, the younger subjects reported mean values
75 mm on the analog scales, whereas the older participants of the present study averaged 42 mm on Day 3 of recovery (Table 2 ). The older participants also did not report soreness under either condition during seated rest, perhaps because type IV muscle afferent (nociceptor) nerve endings were not stimulated in the quiescent QF. Although PGE2 release may increase in with aging (31), type IV free nerve endings may also become less sensitive to prostaglandins. Regardless of the mechanism, a deficit in soreness perception may have significance for older individuals during activities that could exacerbate injury and weakness and/or put them at a greater risk of falling. In this regard, it should be noted that naproxen reduced muscle soreness during activity (Table 2 ) but did not completely abolish muscle injury or weakness. This suggests that older individuals using NSAIDs should be reminded that function may be compromised despite soreness relief.
Although neither CSA nor T2 differed by trial, the relative area of the QF with elevated T2 (i.e., damaged muscle) was less with naproxen. These results are similar to those reported for young adults (10), suggesting that NSAIDs attenuate the expression of the inflammatory response to exercise-induced muscle fiber injury, thereby limiting secondary injury.
Although NSAIDs are commonly used, only a few studies have evaluated their efficacy in younger individuals (10)(11)(32)(33)(34)(35)(36)(37). The investigations that have failed to substantiate the anti-inflammatory properties of NSAIDs after muscle injury have used unreliable markers of muscle injury (plasma creatine phosphokinase) (35), exercised the same musculature repeatedly (35)(36)likely protecting the tissue against further injury after the initial bout (12)(13)and/or examined trained subjects (36)(37) who are less susceptible to muscle injury. Conversely, Hasson and colleagues (33) found that administering ibuprofen 24 hours before or immediately after exercise and for 3 days thereafter attenuated strength decrements and blunted muscle soreness.
Our data strongly suggest that NSAIDs ameliorate muscle injury and dysfunction following novel ECC actions in older persons, although further evaluation of these drugs is necessary. For example, Mishra and colleagues (38) showed that NSAIDs attenuated force decrements in isolated rabbit muscle early after ECC actions but exacerbated the force deficit 1 month after injury. They cautioned against the liberal use of NSAIDs, which is common among elderly persons. On the other hand, approximately 1 month following NSAID therapy in the present study, muscle strength and MR images indicated full recovery from the ECC bout (unpublished results). Nonetheless, the side effects of NSAIDs (e.g., gastrointestinal and hepatic stress) mandate proper medical supervision during prolonged use.
In summary, naproxen sodium administered for 10 days immediately after novel ECC exercise attenuated muscle injury and soreness and improved strength recovery in older individuals. These results suggest that NSAIDs might benefit older individuals embarking on a novel program of physical activity that might induce muscle injury and soreness and/or compromise function during everyday activities.
| Acknowledgments |
|---|
Received June 19, 2000
Accepted July 11, 2000
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
C. D. Black, C. P. Elder, A. Gorgey, and G. A. Dudley High specific torque is related to lengthening contraction-induced skeletal muscle injury J Appl Physiol, March 1, 2008; 104(3): 639 - 647. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Morley Editorial: Hot Topics in Geriatrics J. Gerontol. A Biol. Sci. Med. Sci., January 1, 2003; 58(1): M30 - 36. [Full Text] [PDF] |
||||
![]() |
J. E. Morley, H. M. Perry III, and D. K. Miller Editorial: Something About Frailty J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2002; 57(11): M698 - 704. [Full Text] [PDF] |
||||
![]() |
J. E. Morley and J. H. Flaherty Editorial It's Never Too Late: Health Promotion and Illness Prevention in Older Persons J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2002; 57(6): M338 - 342. [Full Text] |
||||
![]() |
J. E. Morley Editorial: Drugs, Aging, and the Future J. Gerontol. A Biol. Sci. Med. Sci., January 1, 2002; 57(1): M2 - 6. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||
| HOME | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|---|